Copyright Seeking Alpha
Amgen raises 2025 revenue guidance to $35.8B–$36.6B with 14% volume growth, launches AmgenNow platform Nov. 04, 2025 7:37 PM ETAmgen Inc. (AMGN) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: Amgen Inc. (AMGN) Q3 2025 Management View CEO Robert Bradway stated that "Amgen delivered another strong quarter, driven by rising demand for our medicines and meaningful progress across the pipeline. Volume growth once again paced our progress in an environment Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights Amgen reported double-digit revenue and volume growth, raised revenue and EPS guidance, and attributed performance to robust demand and product expansion across all portfolios. Management flagged increasing biosimilar competition for Prolia, a new generic for RAVICTI, slower-than-expected Olpasiran study accrual, and a halted bemarituzumab trial as key growth risks. Amgen is increasing R&D spending, launching direct-to-patient programs like AmgenNow, monitoring biosimilar policy, expanding late-stage pipeline, and emphasizing confidence in new product launches. Recommended For You More Trending News
